Pharmigene, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021
August 11, 2021 at 07:58 pm
Share
Pharmigene, Inc. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was TWD 59.475 million compared to TWD 50.781 million a year ago. Operating loss was TWD 9.217 million compared to TWD 3.943 million a year ago. Net loss was TWD 9.027 million compared to TWD 4.561 million a year ago. Basic loss per share was TWD 0.21 compared to TWD 0.18 a year ago.
Pharmigene Inc is mainly engaged in drug gene diagnosis, functional medical testing services and agency sales of laboratory equipment and consumables. The Company mainly engages in field of genomics science, developing professional drug genetic diagnostic kits, testing technologies, and overall solutions for the research and development of drug genomics in precision medicine. The Company's molecular diagnostic products mainly include AutoEx16 automatic nucleic acid extractor, Clopidogrel drug effectiveness gene CYP2C19*2&*3 test kit, SGE 1502 test suite, SGE 3101 test suite, SGE 5701 test suite, Sega 5801 test kit, SGE B27 test kit, SGE whole blood calculation and extraction kit and others. Testing services include drug genetic testing projects, functional medical testing projects and personalized genetic testing. The Company mainly distributes its products in Taiwan market and other markets.
PHARMIGENE, INC. 
